Akouos Inc. (AKUS): Price and Financial Metrics
GET POWR RATINGS... FREE!
AKUS Stock Price Chart Interactive Chart >
AKUS Price/Volume Stats
| Current price | $2.85 | 52-week high | $15.26 |
| Prev. close | $2.83 | 52-week low | $2.55 |
| Day low | $2.75 | Volume | 81,100 |
| Day high | $2.89 | Avg. volume | 134,360 |
| 50-day MA | $3.77 | Dividend yield | N/A |
| 200-day MA | $7.61 | Market Cap | 98.68M |
Akouos Inc. (AKUS) Company Bio
Akouos, Inc. engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna in 2017 and is headquartered in Boston, MA.
Latest AKUS News From Around the Web
Below are the latest news stories about Akouos Inc that investors may wish to consider to help them evaluate AKUS as an investment opportunity.
BTIG Thinks AKOUOS’s Stock is Going to RecoverBTIG analyst Robert Hazlett reiterated a Buy rating on AKOUOS (AKUS – Research Report) yesterday and set a price target of $35.00. The company's shares closed last Wednesday at $6.02, close to its 52-week low of $5.30. According to TipRanks.com, Hazlett is a 3-star analyst with an average return of 3.1% and a 32.6% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Syndax Pharmaceuticals, and TRACON Pharmaceuticals. AKOUOS has an analyst consensus of Moderate Buy, with a price target consensus of $30.00, representing a 419.0% upside. In a report issued on February 7, H.C. |
H.C. Wainwright Reaffirms Their Buy Rating on AKOUOS (AKUS)H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on AKOUOS (AKUS – Research Report) today and set a price target of $25.00. The company's shares closed last Monday at $5.81, close to its 52-week low of $5.30. According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -17.6% and a 23.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AKOUOS with a $25.00 average price target. |
Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting- Data from two nonclinical studies evaluating protein expression and tolerability support future clinical development of AK-antiVEGF for the treatment of vestibular schwannoma - AAVAnc80 and a supporting cell selective promoter can drive widespread GJB2 expression in supporting cells, while limiting expression in, and loss of, hair cells in mice - AAV-mediated RNAi gene silencing and CRISPR/Cas9 gene editing methods demonstrate a promising reduction of gene of interest protein expression, which |
Akouos to Participate in Upcoming February Virtual Investor ConferencesBOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that members of the management team will participate in two upcoming virtual investor conferences in February: Cowen 2nd Annual Genetic Medicines Summit. Panel discussion including Stacy Price, M.S., chief technical officer, titled “Hot Topics in CMC/Man |
Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter MeetingBOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the Association for Research in Otolaryngology (ARO) 45th Annual Mid-Winter Meeting, which is being held in San Jose, California from February 5 to 9, 2022. The two podium presentations and one poster will highlight no |
AKUS Price Returns
| 1-mo | -12.58% |
| 3-mo | N/A |
| 6-mo | -65.20% |
| 1-year | -77.18% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -66.47% |
| 2021 | -57.14% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...